Ivosidenib (NCT04493164)

Name: Ivosidenib trial for Acute Myeloid Leukemia With Gene Mutations (NCT04493164)
Uploaded: 2026-10-31T21:41:57.500Z
Duration: 1 min 25 s
Description: Ivosidenib trial for Acute Myeloid Leukemia With Gene Mutations (NCT04493164). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04493164.

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: a one-minute explainerNCT044931641 min

Ivosidenib trial for Acute Myeloid Leukemia With Gene Mutations (NCT04493164). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with IDH1-mutated acute myeloid leukemia who can receive intensive chemotherapy. Selected high-risk myelodysplastic syndromes or myeloproliferative neoplasms require investigator approval. Previous CPX-351 is excluded.

The idea: CPX-351 packages daunorubicin and cytarabine chemotherapy in liposomes. Daily oral ivosidenib blocks mutant IDH1, which can interfere with cell maturation. Intravenous chemotherapy starts remission treatment; complete responders proceed to consolidation, then ivosidenib maintenance. Researchers measure responses and safety.

This phase 2 study plans 30 patients. Courtney DiNardo leads at MD Anderson in Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.